The Effect of Ultralow-Dose Transdermal Estradiol on Urinary Incontinence in Postmenopausal Women

OBJECTIVE: To estimate the effect of 2 years of treatment with ultralow-dose transdermal estradiol (E2) on incontinence in postmenopausal women. METHODS: Ultra Low Dose Transdermal estRogen Assessment (ULTRA) was a multicenter, randomized, double-blinded, placebo-controlled trial of unopposed ultralow-dose (0.014 mg/d) transdermal E2 for prevention of osteoporosis in 417 postmenopausal women aged 60 to 80 years. Frequency of incontinence episodes was assessed at baseline and after 4 months and 2 years of treatment using a self-reported questionnaire. We used an intention-to-treat analysis to compare change in incontinence frequency, improved (decreased 2 or more episodes per week), unchanged (increased or decreased no more than 1 episode per week), or worsened (increased 2 or more episodes per week) between the E2 and placebo groups among women with and without at least weekly incontinence at baseline. RESULTS: At baseline, the prevalence of at least weekly incontinence was similar between E2 and placebo groups (43%). After 2 years, there was no difference between groups in the proportions of women with incontinence at baseline whose incontinence improved, worsened, or was unchanged. The odds ratio for worsening incontinence in the E2 compared with placebo group was 1.35 (95% confidence interval 0.75–2.42. In women without incontinence at baseline, the odds of developing at least weekly incontinence after 2 years in the E2 compared with placebo group was not significant (odds ratio 1.2, 95% confidence interval 0.7–2.2). CONCLUSION: Two years of treatment with unopposed ultralow-dose transdermal E2 did not substantially change the frequency of incontinence symptoms or alter the risk of developing at least weekly incontinence. LEVEL OF EVIDENCE: I

[1]  N. Watts,et al.  Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen , 2005, Menopause.

[2]  R. Wallace,et al.  Effects of estrogen with and without progestin on urinary incontinence. , 2005, The Journal of urology.

[3]  S. Cummings,et al.  Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial , 2004, Obstetrics and gynecology.

[4]  S. Cummings,et al.  Effect of Raloxifene on Urinary Incontinence: A Randomized Controlled Trial , 2004, Obstetrics and gynecology.

[5]  F. Grodstein,et al.  Postmenopausal Hormone Therapy and Risk of Developing Urinary Incontinence , 2004, Obstetrics and gynecology.

[6]  G. Schade,et al.  Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis. , 2004, Maturitas.

[7]  L. Cardozo,et al.  A double-blind placebo-controlled trial on the effects of 25 mg estradiol implants on the urge syndrome in postmenopausal women , 2003, International Urogynecology Journal.

[8]  S. Jackson,et al.  Oestrogens for urinary incontinence in women. , 2003, The Cochrane database of systematic reviews.

[9]  C. Christiansen,et al.  Adverse effects of a SERM (Levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal. , 2003, Maturitas.

[10]  P. Abrams,et al.  The effect of oestradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence , 2002, BJOG : an international journal of obstetrics and gynaecology.

[11]  S. Hendrix,et al.  Effect of Selective Estrogen Receptor Modulators on Reproductive Tissues Other Than Endometrium , 2001, Annals of the New York Academy of Sciences.

[12]  G. Greendale,et al.  Effects of Oral Estrogen and Progestin on the Lower Urinary Tract Among Female Nursing Home Residents , 2001, Journal of the American Geriatrics Society.

[13]  E. Vittinghoff,et al.  Postmenopausal Hormones and Incontinence: The Heart and Estrogen/Progestin Replacement Study , 2001, Obstetrics and Gynecology.

[14]  P. Hilton,et al.  Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status , 2000, BJU international.

[15]  E. Baracat,et al.  Power Doppler of the Urethra in Continent or Incontinent, Pre- and Postmenopausal Women , 2000, International Urogynecology Journal.

[16]  L. Plouffe,et al.  Uterine Effects of 3‐Year Raloxifene Therapy in Postmenopausal Women Younger Than Age 60 , 2000, Obstetrics and gynecology.

[17]  S. Brookes,et al.  The effect of oestrogen supplementation on post‐menopausal urinary stress incontinence: a double‐blind placebo‐controlled trial , 1999, British journal of obstetrics and gynaecology.

[18]  Jeanette S. Brown,et al.  Reproductive and Hormonal Risk Factors for Urinary Incontinence in Later Life: A Review of the Clinical and Epidemiologic Literature , 1998, Journal of the American Geriatrics Society.

[19]  D. Thom.  Variation in Estimates of Urinary Incontinence Prevalence in the Community: Effects of Differences in Definition, Population Characteristics, and Study Type , 1998, Journal of the American Geriatrics Society.

[20]  U. Ulmsten,et al.  Paraurethral connective tissue in stress‐incontinent women after menopause , 1998, Acta obstetricia et gynecologica Scandinavica.

[21]  A. Bailey,et al.  Analysis of collagen status in premenopausal nulliparous women with genuine stress incontinence , 1997, British journal of obstetrics and gynaecology.

[22]  D. McClish,et al.  Efficacy of Estrogen Supplementation in the Treatment of Urinary Incontinence , 1996, Obstetrics and gynecology.

[23]  U. Ulmsten,et al.  Changes in paraurethral connective tissue at menopause are counteracted by estrogen. , 1996, Maturitas.

[24]  D. McClish,et al.  Estrogen Therapy in the Management of Urinary Incontinence in Postmenopausal Women: A Meta-Analysis. First Report of the Hormones and Urogenital Therapy Committee , 1994, Obstetrics and gynecology.

[25]  L. Cardozo,et al.  Oestriol in the treatment of postmenopausal urgency: a multicentre study. , 1993, Maturitas.

[26]  E. Ooms,et al.  The effect of estriol on the cytology of urethra and vagina in postmenopausal women with genito-urinary symptoms. , 1993, European journal of obstetrics, gynecology, and reproductive biology.

[27]  A. Bergman,et al.  Estrogen effects on the urethra: beneficial effects in women with genuine stress incontinence. , 1993, Obstetrical & gynecological survey.

[28]  U. Ulmsten,et al.  Localization of steroid hormone receptors in the pelvic muscles. , 1993, European journal of obstetrics, gynecology, and reproductive biology.

[29]  U. Ulmsten,et al.  The round ligament: a target organ for steroid hormones. , 1993, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[30]  D. Sacchini,et al.  [Transvaginal estrogen therapy in urinary stress incontinence]. , 1990, Minerva Ginecologica.

[31]  B. Faragher,et al.  Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women , 1987, British journal of obstetrics and gynaecology.

[32]  L. Mattsson,et al.  Fatty acid composition of serum lecithin and cholesterol ester in the normal menstrual cycle. , 1985, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[33]  M. Karram,et al.  Changes in urethral cytology following estrogen administration. , 1990, Gynecologic and obstetric investigation.

[34]  H. O. Beisland,et al.  Urethral sphincteric insufficiency in postmenopausal females: treatment with phenylpropanolamine and estriol separately and in combination. A urodynamic and clinical evaluation. , 1984, Urologia internationalis.

[35]  U. Ulmsten,et al.  Effects of oestradiol and combined norephedrin and oestradiol treatment on female stress incontinence. , 1980, Zentralblatt fur Gynakologie.

[36]  P. McCullagh.  Regression Models for Ordinal Data , 1980 .